These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1980 related items for PubMed ID: 19695244

  • 1. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
    Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D.
    Eur J Pharmacol; 2009 Oct 12; 620(1-3):27-35. PubMed ID: 19695244
    [Abstract] [Full Text] [Related]

  • 2. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
    Newman-Tancredi A, Assié MB, Martel JC, Cosi C, Slot LB, Palmier C, Rauly-Lestienne I, Colpaert F, Vacher B, Cussac D.
    Br J Pharmacol; 2007 May 12; 151(2):237-52. PubMed ID: 17375087
    [Abstract] [Full Text] [Related]

  • 3. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P, Newman-Tancredi A, Loock T, Cussac D.
    Eur J Pharmacol; 2008 Feb 26; 581(1-2):37-46. PubMed ID: 18190908
    [Abstract] [Full Text] [Related]

  • 4. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A.
    J Pharmacol Exp Ther; 2005 Oct 26; 315(1):265-72. PubMed ID: 15987834
    [Abstract] [Full Text] [Related]

  • 5. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.
    Ichikawa J, Meltzer HY.
    J Pharmacol Exp Ther; 1999 Dec 26; 291(3):1227-32. PubMed ID: 10565846
    [Abstract] [Full Text] [Related]

  • 6. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.
    Assié MB, Bardin L, Auclair A, Consul-Denjean N, Sautel F, Depoortère R, Newman-Tancredi A.
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun 26; 375(4):241-50. PubMed ID: 17453175
    [Abstract] [Full Text] [Related]

  • 7. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R, Bardin L, Auclair AL, Kleven MS, Prinssen E, Colpaert F, Vacher B, Newman-Tancredi A.
    Br J Pharmacol; 2007 May 26; 151(2):253-65. PubMed ID: 17375086
    [Abstract] [Full Text] [Related]

  • 8. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
    Gogos A, Kwek P, Chavez C, van den Buuse M.
    J Pharmacol Exp Ther; 2010 Apr 26; 333(1):218-27. PubMed ID: 20042529
    [Abstract] [Full Text] [Related]

  • 9. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G.
    J Pharmacol Exp Ther; 1998 Sep 26; 286(3):1341-55. PubMed ID: 9732398
    [Abstract] [Full Text] [Related]

  • 10. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
    Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A.
    Br J Pharmacol; 2007 May 26; 151(2):266-77. PubMed ID: 17375085
    [Abstract] [Full Text] [Related]

  • 11. L-type calcium channel blockade on haloperidol-induced c-Fos expression in the striatum.
    Lee J, Rushlow WJ, Rajakumar N.
    Neuroscience; 2007 Nov 09; 149(3):602-16. PubMed ID: 17913375
    [Abstract] [Full Text] [Related]

  • 12. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
    Assié MB, Mnie-Filali O, Ravailhe V, Benas C, Marien M, Bétry C, Zimmer L, Haddjeri N, Newman-Tancredi A.
    Eur J Pharmacol; 2009 Apr 01; 607(1-3):74-83. PubMed ID: 19326477
    [Abstract] [Full Text] [Related]

  • 13. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
    Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B.
    J Med Chem; 2007 Feb 22; 50(4):865-76. PubMed ID: 17300168
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A, Artaiz I, Innerárity A, Del Olmo E, Castro E, Labeaga L, Pazos A, Orjales A.
    Neuropharmacology; 2006 Jul 22; 51(1):129-40. PubMed ID: 16643965
    [Abstract] [Full Text] [Related]

  • 15. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
    Bruins Slot LA, Kleven MS, Newman-Tancredi A.
    Neuropharmacology; 2005 Dec 22; 49(7):996-1006. PubMed ID: 16009387
    [Abstract] [Full Text] [Related]

  • 16. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.
    Pharmacol Biochem Behav; 2005 Oct 22; 82(2):361-72. PubMed ID: 16216322
    [Abstract] [Full Text] [Related]

  • 17. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
    Kleven MS, Barret-Grévoz C, Bruins Slot L, Newman-Tancredi A.
    Neuropharmacology; 2005 Aug 22; 49(2):135-43. PubMed ID: 15996562
    [Abstract] [Full Text] [Related]

  • 18. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
    Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, Kawai Y.
    Neuropharmacology; 2008 Oct 22; 55(5):717-23. PubMed ID: 18585397
    [Abstract] [Full Text] [Related]

  • 19. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ, Svenningsson P, Ashby CR, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, Iob L, Veiga S, Gobert A.
    J Pharmacol Exp Ther; 2008 Feb 22; 324(2):600-11. PubMed ID: 18024787
    [Abstract] [Full Text] [Related]

  • 20. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex.
    Sato M, Ago Y, Koda K, Nakamura S, Kawasaki T, Baba A, Matsuda T.
    Eur J Pharmacol; 2007 Mar 22; 559(2-3):155-60. PubMed ID: 17258195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 99.